Agenus unveils new and updated botensilimab data in colorectal, pancreatic, lung, melanoma, and sarcoma

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a leader in developing novel immunological agents to treat cancers, today announced first-time and updated data from its ongoing botensilimab/balstilimab (bot/bal) clinical programs in advanced colorectal cancer (crc), neoadjuvant crc, pancreatic cancer, non-small cell lung cancer (nsclc), melanoma, and sarcoma. members of the agenus leadership team along with key opinion leaders will discuss these findings during a live webcast at.
AGEN Ratings Summary
AGEN Quant Ranking